Scandion Oncology: Outcome of right issue announced

Redeye comments on the outcome of Scandion’s rights issue, and we resume our coverage. We adjust our valuation for increased cash and shares outstanding.

CB

Christian Binder

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.